Intra-Cellular Therapies. has been granted a patent for methods to treat acute depression and anxiety. The approach involves administering a specific ligand that targets 5-HT2A and mu-opioid receptors, enhancing mTOR signaling and reducing neuroinflammation in patients. GlobalData’s report on Intra-Cellular Therapies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intra-Cellular Therapies, Peptide pharmacophores was a key innovation area identified from patents. Intra-Cellular Therapies's grant share as of June 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12023331B2 outlines a method for treating acute depression and acute anxiety through the administration of a specific compound, referred to as Compound of Formula I. The claims detail various forms of this compound, including its tosylate salt form, and specify the administration routes, which can include oral, subcutaneous, or intravenous methods. The treatment is designed for patients experiencing conditions such as acute anxiety, acute depression, and treatment-resistant depression, particularly those who have not adequately responded to existing antidepressant therapies. The method emphasizes a once-daily dosage of 1 to 100 mg of the compound, potentially in combination with other anxiolytic or antidepressant agents, while ensuring that the treatment does not induce sedation, dissociation, or other adverse effects.
Additionally, the claims highlight the therapeutic mechanisms of the treatment, including the enhancement of mTOR signaling and reduction of neuroinflammation. The patent also specifies that patients may show an acute response to treatment within a short timeframe, ranging from less than two days to one week. Furthermore, the method allows for concurrent administration of NMDA receptor antagonists or allosteric modulators, broadening the potential therapeutic applications. Overall, the patent presents a comprehensive approach to addressing acute mental health conditions, focusing on both efficacy and safety in treatment protocols.
To know more about GlobalData’s detailed insights on Intra-Cellular Therapies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
